Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 14/20 | 0.48 |
| ▸ | CLK1 | P49759 | 5/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.48 |
| ▸ | CLK2 | P49760 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16161703 | 0.99 | CLK4 (0.48) | CLK4CLK1DYRK1ACLK2DYRK1B | |
| SCHEMBL780356 | 0.89 | PDGFRB (0.56) | CLK4ALDH1A1HPGDKDM4EPDGFRB | |
| SCHEMBL781792 | 0.88 | MKNK2 (0.46) | CLK4DYRK1ACLK2PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL16162188 | 0.87 | MKNK2 (0.45) | CLK4DYRK1ACLK2PDGFRBPDGFRA | |
| SCHEMBL780371 | 0.84 | ROCK2 (0.51) | CLK4CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL780558 | 0.84 | ROCK2 (0.51) | PDGFRBPDGFRA | |
| SCHEMBL782152 | 0.84 | ROCK2 (0.55) | CLK4PDGFRBPDGFRA | |
| SCHEMBL781920 | 0.84 | ROCK2 (0.43) | PDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL16161764 | 0.83 | ROCK2 (0.54) | CLK4PDGFRBPDGFRA | |
| SCHEMBL781535 | 0.83 | TPH1 (0.44) | CLK4CLK2PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | claimed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | claimed |
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | RPS6KA1, RPS6KA3, MTOR | CLK4 514/4885CLK1 533/4885DYRK1A 136/4885 |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | CLK4 312/4885CLK1 337/4885DYRK1A 351/4885 |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | RPS6KA1, RPS6KA3, MTOR | CLK4 514/4885CLK1 533/4885DYRK1A 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.